Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
18 hedge funds and large institutions have $40.7M invested in Ambrx Biopharma Inc in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 4 closing their positions.
126% more capital invested
Capital invested by funds: $18M → $40.7M (+$22.7M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
13% more funds holding
Funds holding: 16 → 18 (+2)
3.28% more ownership
Funds ownership: 43.13% → 46.41% (+3.3%)
74% less call options, than puts
Call options by funds: $61K | Put options by funds: $233K
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$8.67M |
| 2 |
AGM
Alpine Global Management
New York
|
+$53.4K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$22.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.9K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.08M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$1.61M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.02M |
| 5 |
Millennium Management
New York
|
-$108K |
AMAM Hedge Fund Activity: Q4 2022 in Review
18 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q4 2022, worth a combined $40.7M — up 126% from $18M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AMAM positions and 4 closed out — a net gain of 2 holders — while 1 added to existing stakes and 8 trimmed.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $8.67M. The largest seller was BlackRock, exiting entirely with an estimated $3.08M sold.
- 18 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q4 2022, up from 16 in Q3 2022.
- Funds reported $40.7M of Ambrx Biopharma Inc stock for Q4 2022, up 126% quarter-over-quarter.
- 6 funds opened new Ambrx Biopharma Inc positions in Q4 2022 and 4 closed out, a net change of +2 holders.
- The largest Ambrx Biopharma Inc buyer in Q4 2022 was Darwin Global Management, an estimated $8.67M added.
- The largest Ambrx Biopharma Inc seller in Q4 2022 was BlackRock, an estimated $3.08M sold.
Based on aggregated 13F filings for Q4 2022.